Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1321-1324
Published online before print April 14, 2005,
doi: 10.1161/01.ATV.0000166521.90532.44
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:1321.)
© 2005 American Heart Association, Inc.
New Links Between Inflammation and Thrombosis
Denisa D. Wagner
From the CBR Institute for Biomedical Research and Department of Pathology, Harvard Medical School, Boston, Mass.
Correspondence to Denisa D. Wagner, CBR Institute for Biomedical Research, 800 Huntington Ave, Boston, MA 02115. E-mail wagner{at}cbr.med.harvard.edu
 |
Abstract
|
|---|
This article is a summary of the Sol Sherry Lecture of the Council
on Arteriosclerosis, Thrombosis, and Vascular Biology, which
was presented at the Scientific Sessions of the American Heart
Association in November 2004. It highlights work from our laboratory,
focusing mainly on new aspects of P-selectin and CD40L (CD154)
biology and on the interplay of platelets and leukocytes in
thrombosis and inflammation.
This article is a summary of the Sol Sherry Lecture of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, which was presented at the Scientific Sessions of the American Heart Association in November 2004. The article focuses mainly on new aspects of P-selectin and CD40L (CD154) biology and on the interplay of platelets and leukocytes in thrombosis and inflammation.
Key Words: platelets inflammation adhesion molecules Weibel-Palade body
 |
Introduction
|
|---|
It was an honor to present a lecture in the memory of Dr Sol
Sherry (1916 to 1993), who is known among hematologists as the
"father of thrombolytic therapy." Sherry is also acclaimed for
the large number of trainees whose careers he helped build.
Even I am part of this lineage because he was a mentor to Dr
Victor Marder, who, in turn, mentored me in my first faculty
position in Rochester, NY. It was there that we found that Weibel-Palade
bodies, organelles specific to endothelial cells, are secretory
granules and that they contain very large von Willebrand factor
(vWF) multimers.
1,2 These multimers are most potent in promoting
platelet adhesion during the first step of hemostasis. Several
years later, it became apparent that P-selectin is stored in
these same granules
3,4and mediates adhesion to leukocytes.
5 Thus, we established that the Weibel-Palade body is a prominent
link between inflammation and thrombosis. A myriad of stimulatory
mediators that result from injury or inflammation, such as thrombin
and histamine, cause Weibel-Palade body secretion, leading to
surface expression of vWF and P-selectin (
Figure). Whereas P-selectin
mediates leukocyte rolling,
6,7 both of these Weibel-Palade body
components can support resting platelet rolling under different
shear rate conditions.
8,9 Activated platelets can also roll
on endothelium via their P-selectin but only when the endothelium
is inflamed and expresses a yet unidentified P-selectin ligand.
10 Inflamed endothelium also strongly supports leukocyte rolling
because it expresses new ligands induced by inflammation such
as E-selectin and vascular cell adhesion molecule-1 that, like
P-selectin, mediate leukocyte rolling. Because of the similarities
between the behavior of leukocytes and platelets and the molecular
mechanisms recruiting both cell types to the vessel wall, we
asked: Are platelets involved in inflammation? Are leukocytes
involved in hemostasis? As is discussed below, the answer to
both questions is yes.

View larger version (98K):
[in this window]
[in a new window]
|
Interplay of inflammation and hemostasis.41 On endothelial activation through vascular injury or inflammation, Weibel-Palade bodies release their contents, leading to vWF and P-selectin expression. These adhesion molecules mediate platelet and leukocyte rolling on the vessel wall. The rolling step is crucial for leukocyte extravasation and likely helps in the formation of the platelet plug. Neutrophils are depicted in yellow and monocytes in pale blue. P-selectin can signal into leukocytes producing procoagulant MPs (pale blue) containing TF that are recruited into the growing thrombus, where they facilitate generation of thrombin and fibrin. Activated platelets also express the cytokine CD40L, which promotes platelet activation by binding to the major platelet integrin. Platelet CD40L can also further stimulate inflammatory responses in surrounding endothelium. (Adapted from Frenette and Wagner.41)
|
|
 |
Role of Platelets in Chronic and Acute Inflammation
|
|---|
The goal of inflammation is to rapidly recruit leukocytes to
the site of injury or infection. P-selectin on endothelium plays
an important role in neutrophil and monocyte recruitment.
7,11 Therefore, it was no big surprise when Arthur Beaudets
and our groups found that P-selectin is important for the migration
of monocytes to atherosclerotic lesions in mouse models of atherosclerosis.
12 But P-selectin is also expressed at high density on activated
platelets after it is released from

-granules
4 and could help
in leukocyte recruitment
13 to atherosclerotic lesions. Therefore,
Peter Burger asked whether it is platelet or endothelial P-selectin
that is most important for atherosclerosis.
14 The question was
answered by performing bone marrow transplants generating animals
with only endothelial or platelet P-selectin on the apolipoprotein
E-deficient (apoE/) background that promotes atherosclerosis.
The chimeric animals were allowed to age for 7 months, and then
their aortic sinus lesions were analyzed. Only animals with
endothelial P-selectin developed lesions of significant size,
demonstrating that endothelial P-selectin is crucial for atherosclerotic
lesion growth. Interestingly, a comparison of animals expressing
endothelial P-selectin showed 30% larger lesions in mice with
platelet P-selectin than in mice lacking the platelet P-selectin.
Thus, platelets and their P-selectin contribute to atherosclerotic
lesion development. The degree of lesion maturation (presence
of smooth muscle cells and calcification) was dependent on endothelial
as well as platelet P-selectin.
14 Therefore, it appears that
signaling induced by P-selectin may stimulate monocytes/macrophages
to produce more chemoattractants or growth factors, leading
to larger numbers of smooth muscle cells in the lesions. Russell
Ross had already proposed a role for platelets in atherosclerosis
in the 1980s, but it was only in 2002 to 2003 that 3 groups
demonstrated this experimentally through very different approaches.
15,16 In addition to our work described above, Massberg et al showed
that platelet depletion or inhibition of platelet adhesion delayed
fatty streak (early atherosclerotic lesion) formation in mice,
17 and Leys group observed that repeated infusion over several
weeks of activated platelets into apoE/ mice promoted
lesion formation.
18 Here again, platelet P-selectin was required
for the atherogenic effect.
Because platelet P-selectin is expressed only on activated platelets, for it to have an effect in the bone marrow transplant study described above,14 some platelets also had to become activated in circulation. In our group, Vandana Dole is now asking whether the presence of large numbers of activated platelets, such as would occur at the time of surgery or in pathologic situations such as unstable angina, could systemically affect endothelial function and perhaps induce inflammation. She has found that numbers of rolling leukocytes were increased several-fold in wild-type mice 2 hours after infusion of wild-type-activated platelets. The effect was transient because leukocyte rolling returned to baseline levels 7 hours after infusion. Resting platelets or activated platelets lacking P-selectin did not activate endothelium (V. Dole, unpublished observations, 2004). Thus, it appears that the presence of activated platelets in circulation rapidly and transiently induces systemic leukocyte rolling, giving the animal a head start on inflammation. Whether this effect is directly onto endothelium or by an intermediate generated from platelet/leukocyte interaction via P-selectin remains to be clarified. What is evident now is that P-selectin expressed on endothelium or on activated platelets is a major player in acute and chronic inflammation.
 |
Procoagulant Activity of P-Selectin
|
|---|
Because P-selectin is stored in the same granules as the platelet
adhesion molecule vWF, could it also have a role in hemostasis?
An early observation by Palabrica et al indicated that it might
be the case. She observed that in the presence of an antibody
to P-selectin, less fibrin was deposited on platelets adherent
to thrombogenic grafts implanted in baboons.
19 The next evidence
that P-selectin regulates fibrin deposition came from transgenic
mice. These were P-selectin-deficient (P-selectin/)
mice,
7 and mice expressing P-selectin without the cytoplasmic
tail (

CT) mice.
20 The P-selectin cytoplasmic domain is necessary
to target P-selectin to Weibel-Palade bodies.
21 Indeed, these
mice did not store P-selectin in endothelial cells, and excessive
amounts of the P-selectin extracellular domain were found circulating
in plasma, indicating that the protein was proteolytically shed
from the plasma membrane. Patrick André studied thrombus
formation in a capillary flow chamber coated with collagen that
was directly linked to the vena cava of these mice. He observed
striking differences in the amount of fibrin deposited on the
forming platelet thrombi after 2 minutes of perfusion.
22 There
was no fibrin detected in chambers perfused with P-selectin/
blood, some fibrin formed with wild-type blood, and most fibrin
was deposited in chambers perfused with

CT blood. Interestingly,
the plasma from the

CT mice also clotted faster than wild-type.
22 We concluded that the plasma of these mice was procoagulant
because it contained elevated numbers of leukocyte-derived microparticles
(MPs) containing tissue factor (TF), the primary initiator of
the coagulation cascade.
23 These MPs represented what is now
called the "blood-borne TF" described by Nemerson et al.
24 The
presence of elevated levels of P-selectin was found to be responsible
for the presence of the MPs because the procoagulant state of
the

CT mice could be reproduced by infusion of chimeric molecules
containing P-selectin linked to immunoglobulin backbone (P-sel-Ig).
22
 |
How Does P-Selectin Induce Procoagulant Activity and Promote Fibrin Deposition?
|
|---|
P-selectin appears to have 2 distinct roles in the process.
First, through signaling by P-selectin glycoprotein ligand-1
(PSGL-1), it induces the formation of MPs from leukocytes, most
likely monocytes.
25 Some of the MPs contain TF in addition to
the procoagulant phospholipids.
22 The plasma levels of these
MPs depend on levels of P-selectin expression. Thus, significant
injury or chronic inflammation might increase the P-selectin/PSGL-1dependent
MP production. In mice, MP count increases with age, but this
is not the case in PSGL-1/ mice, indicating that
the increase in MP count perhaps results from more inflammation
(P-selectin expression) with age.
25 Paul Ridker has shown that
elevated soluble P-selectin (sP-selectin) in plasma increases
the risk of future cardiovascular events such as myocardial
infarction and stroke.
26 Thus, high levels of sP-selectin appear
undesirable and may reflect poor health. Preliminary results
from our laboratory indicate that the

CT mice, with several-fold
elevated sP-selectin and consequently presenting unusually high
procoagulant activity, have defects in their blood-brain barrier
(J. Kisucka, unpublished results, 2004), showing how widely
disregulated P-selectin expression can affect vascular function.
A second role of P-selectin in augmenting coagulation is in the recruitment of leukocyte-derived MPs to thrombi (Figure). P-selectin expressed on activated platelets captures the MPs via PSGL-1.27,28 This concentrates the procoagulant activity at the thrombus site, just where it is needed. The importance of this blood-borne TF may depend on the quality of the injury. In situations in which lots of TF is exposed to blood, the blood-borne TF may be less important than in puncture wounds.29,30 MP-containing TF may also stabilize fibrin long after it was deposited and when the wound is fully covered by platelets. This is likely why inhibitors of P-selectin/PSGL-1 may act as thrombolytic agents dipping the coagulation balance toward thrombolysis.31 Another situation in which blood-borne TF may play an important role is thrombosis at sites of stasis. Ischemia causes upregulation of P-selectin on endothelium, and this may promote capture of MPs and explain formation of larger thrombi in deep vein thrombosis models in the
CT mice than in wild-type.32
Could the procoagulant power of P-selectin be captured in a situation in which the intrinsic coagulation pathway is defective? Apparently, yes. To strengthen the extrinsic pathway of coagulation and thus the total capacity to generate thrombin, we treated mice deficient in Factor VIII with P-sel-Ig to produce more MPs. In this way, in the mouse model of hemophilia A, we could normalize plasma-clotting parameters and tail-bleeding time.25 Our results point to a new strategy for treatment of hemophilia patients, in particular, those with alloantibodies.31
 |
Role of CD40 Ligand (CD40L) in Thrombosis
|
|---|
Another new molecular link between inflammation and thrombosis
is the cytokine CD40L (also called CD154 or gp39). CD40L is
a trimeric transmembrane protein that is a member of the tumor
necrosis factor (TNF) family.
33 It is not only expressed on
the cells of the immune system but also on activated platelets.
34 Similar to P-selectin, CD40L is stored in platelets and translocates
to the plasma membrane on activation. CD40L is an important
molecule regulating immune responses by interacting with its
receptor CD40, a member of the TNF receptor family. This interaction
induces antibody isotype switching, and absence of CD40L in
humans results in hyper IgM syndrome.
35 CD40L binding to CD40
on endothelium induces inflammation, and this biological activity
is also preserved in platelet CD40L.
34 The interaction of platelet
CD40L with CD40, which is also found on platelets, induces CD40L
shedding by proteolytic cleavage, and the soluble protein (sCD40L)
no longer has the inflammatory activity of the transmembrane
receptor.
36 The proinflammatory activity of CD40L is also reflected
in its prominent role in atherosclerosis.
37 Because CD40L is
expressed on activated platelets, we asked whether it plays
a role in thrombosis and whether this role is dependent on CD40.
Our initial observations showed that thrombi forming in injured
arterioles in CD40L-deficient mice were highly unstable and
that, in contrast, CD40-deficient mice had normal thrombus formation.
David Phillips noted that CD40L has a KGD sequence, a sequence
known to bind to the major platelet integrin

IIbß3.
38 His laboratory provided us with recombinant forms of sCD40L.
Whereas the wild-type version of the protein could, on infusion,
restore stability of CD40L-deficient thrombi, the protein mutated
in the KGD sequence could not.
39 Binding studies confirmed that
indeed, sCD40L binds to the platelet integrin via the KGD sequence
39 and showed that CD40L triggers "outside-in" signaling in the
platelet by inducing

IIbß3 cytoplasmic domain phosphorylation.
40
In conclusion, there are many links between the processes of thrombosis and inflammation (Figure). In nature, hemostatic and inflammatory responses often occur together as, for example, a reaction to an animal bite that produces bleeding and infection. Therefore, it is not surprising that some of the first response mechanisms, such as secretion of Weibel-Palade bodies, are shared in thrombosis and inflammation. In addition, it is apparent that molecules involved in these defense mechanisms, such as P-selectin and CD40L, may have independent functions in both pathways. The physiological processes of thrombosis and inflammation should not be viewed in isolation because they greatly influence each other, and the more we continue to scrutinize them, the more interconnections we are likely to find.
 |
Acknowledgments
|
|---|
The work from our laboratory was funded by grants R37 HL41002,
R01 HL53756, and P01 HL56949 from the National Heart, Lung,
and Blood Institute of the National Institutes of Health. I
would like to thank Jaime Lazarte and Lesley Cowan for help
with preparation of this manuscript.
 |
Footnotes
|
|---|
This is an invited article based on the Sol Sherry Lecture of
the Council on Arteriosclerosis, Thrombosis, and Vascular Biology,
presented at the Scientific Sessions of the American Heart Association,
November 2004.
Received March 10, 2005;
accepted April 6, 2005.
 |
References
|
|---|
- Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol. 1982; 95: 355360.[Abstract/Free Full Text]
- Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell. 1986; 46: 185190.[CrossRef][Medline]
[Order article via Infotrieve]
- Bonfanti R, Furie BC, Furie B, Wagner DD. PADGEM (GMP140) is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1989; 73: 11091112.[Abstract/Free Full Text]
- McEver RP, Beckstead JH, Moore KL, Marshall-Carlson L, Bainton DF. GMP-140, a platelet alpha-granule membrane protein, is also synthesized by vascular endothelial cells and is localized in Weibel-Palade bodies. J Clin Invest. 1989; 84: 9299.
- Ley K. The role of selectins in inflammation and disease. Trends Mol Med. 2003; 9: 263268.[CrossRef][Medline]
[Order article via Infotrieve]
- Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 1991; 65: 859873.[CrossRef][Medline]
[Order article via Infotrieve]
- Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD. Leukocyte rolling and extravasation are severely compromised in P selectin-deficient mice. Cell. 1993; 74: 541554.[CrossRef][Medline]
[Order article via Infotrieve]
- Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci U S A. 1995; 92: 74507454.[Abstract/Free Full Text]
- Andre P, Denis CV, Ware J, Saffaripour S, Hynes RO, Ruggeri ZM, Wagner DD. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood. 2000; 96: 33223328.[Abstract/Free Full Text]
- Frenette PS, Moyna C, Hartwell DW, Lowe JB, Hynes RO, Wagner DD. Platelet-endothelial interactions in inflamed mesenteric venules. Blood. 1998; 91: 13181324.[Abstract/Free Full Text]
- Johnson RC, Mayadas TN, Frenette PS, Mebius RE, Subramaniam M, Lacasce A, Hynes RO, Wagner DD. Blood cell dynamics in P-selectin-deficient mice. Blood. 1995; 86: 11061114.[Abstract/Free Full Text]
- Dong ZM, Wagner DD. Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med. 1998; 132: 369375.[CrossRef][Medline]
[Order article via Infotrieve]
- Yeo EL, Sheppard JA, Feuerstein IA. Role of P-selectin and leukocyte activation in polymorphonuclear cell adhesion to surface adherent activated platelets under physiologic shear conditions (an injury vessel wall model). Blood. 1994; 83: 24982507.[Abstract/Free Full Text]
- Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood. 2003; 101: 26612666.[Abstract/Free Full Text]
- Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol. 2003; 23: 21312137.[Abstract/Free Full Text]
- Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004; 14: 1822.[CrossRef][Medline]
[Order article via Infotrieve]
- Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196: 887896.[Abstract/Free Full Text]
- Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003; 9: 6167.[CrossRef][Medline]
[Order article via Infotrieve]
- Palabrica T, Lobb R, Furie BC, Aronovitz M, Benjamin C, Hsu YM, Sajer SA, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992; 359: 848851.[CrossRef][Medline]
[Order article via Infotrieve]
- Hartwell DW, Mayadas TN, Berger G, Frenette PS, Rayburn H, Hynes RO, Wagner DD. Role of P-selectin cytoplasmic domain in granular targeting in vivo and in early inflammatory responses. J Cell Biol. 1998; 143: 11291141.[Abstract/Free Full Text]
- Disdier M, Morrissey JH, Fugate RD, Bainton DF, McEver RP. Cytoplasmic domain of P-selectin (CD62) contains the signal for sorting into the regulated secretory pathway. Mol Biol Cell. 1992; 3: 309321.[Abstract]
- Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000; 97: 1383513840.[Abstract/Free Full Text]
- Eilertsen KE, Osterud B. Tissue factor: (patho)physiology and cellular biology. Blood Coagul Fibrinolysis. 2004; 15: 521538.[Medline]
[Order article via Infotrieve]
- Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999; 96: 23112315.[Abstract/Free Full Text]
- Hrachovinova I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003; 9: 10201025.[CrossRef][Medline]
[Order article via Infotrieve]
- Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001; 103: 491495.[Abstract/Free Full Text]
- Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood. 2000; 96: 170175.[Abstract/Free Full Text]
- Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med. 2003; 197: 15851598.[Abstract/Free Full Text]
- Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, Furie B. Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood. 2004; 104: 31903197.[Abstract/Free Full Text]
- Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005; 105: 192198.[Abstract/Free Full Text]
- Cambien B, Wagner DD. A new role in hemostasis for the adhesion receptor P-selectin. Trends Mol Med. 2004; 10: 179186.[CrossRef][Medline]
[Order article via Infotrieve]
- Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003; 38: 10751089.[CrossRef][Medline]
[Order article via Infotrieve]
- van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000; 67: 217.[Abstract]
- Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591594.[CrossRef][Medline]
[Order article via Infotrieve]
- Ramesh N, Geha RS, Notarangelo LD. CD40 ligand and the hyper-IgM syndrome. In: Ochs HD, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press; 1999.
- Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001; 98: 10471054.[Abstract/Free Full Text]
- Lutgens E, Gorelik L, Daemen MJ, de Muinck ED, Grewal IS, Koteliansky VE, Flavell RA. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999; 5: 13131316.[CrossRef][Medline]
[Order article via Infotrieve]
- Scarborough RM, Naughton MA, Teng W, Rose JW, Phillips DR, Nannizzi L, Arfsten A, Campbell AM, Charo IF. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem. 1993; 268: 10661073.[Abstract/Free Full Text]
- Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002; 8: 247252.[CrossRef][Medline]
[Order article via Infotrieve]
- Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci U S A. 2003; 100: 1236712371.[Abstract/Free Full Text]
- Frenette PS, Wagner DD. Adhesion molecules-part II: blood vessels and blood cells. N Engl J Med. 1996; 335: 4345.[Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. K. Chauhan, J. Kisucka, A. Brill, M. T. Walsh, F. Scheiflinger, and D. D. Wagner
ADAMTS13: a new link between thrombosis and inflammation
J. Exp. Med.,
September 1, 2008;
205(9):
2065 - 2074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Tjwa, L. Bellido-Martin, Y. Lin, E. Lutgens, S. Plaisance, F. Bono, N. Delesque-Touchard, C. Herve, R. Moura, A. D. Billiau, et al.
Gas6 promotes inflammation by enhancing interactions between endothelial cells, platelets, and leukocytes
Blood,
April 15, 2008;
111(8):
4096 - 4105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Pacienza, R. G. Pozner, G. A. Bianco, L. P. D'Atri, D. O. Croci, S. Negrotto, E. Malaver, R. M. Gomez, G. A. Rabinovich, and M. Schattner
The immunoregulatory glycan-binding protein galectin-1 triggers human platelet activation
FASEB J,
April 1, 2008;
22(4):
1113 - 1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Salanova, M. Choi, S. Rolle, M. Wellner, F. C. Luft, and R. Kettritz
beta2-Integrins and Acquired Glycoprotein IIb/IIIa (GPIIb/IIIa) Receptors Cooperate in NF-{kappa}B Activation of Human Neutrophils
J. Biol. Chem.,
September 21, 2007;
282(38):
27960 - 27969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Touma, S. Atweh, L. Kibbi, and T. Arayssi
Longitudinal myelitis in patient with systemic lupus erythematosus, homozygous prothrombin G20210A and heterozygous MTHFR 677T
Lupus,
July 1, 2007;
16(7):
517 - 520.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Li, S. He, M. Blomback, and P. Hjemdahl
Platelet Activity, Coagulation, and Fibrinolysis During Exercise in Healthy Males: Effects of Thrombin Inhibition by Argatroban and Enoxaparin
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2007;
27(2):
407 - 413.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Morel, F. Toti, B. Hugel, B. Bakouboula, L. Camoin-Jau, F. Dignat-George, and J.-M. Freyssinet
Procoagulant Microparticles: Disrupting the Vascular Homeostasis Equation?
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2006;
26(12):
2594 - 2604.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Sarda-Mantel, M. Coutard, F. Rouzet, O. Raguin, J.-M. Vrigneaud, F. Hervatin, G. Martet, Z. Touat, P. Merlet, D. Le Guludec, et al.
99mTc-Annexin-V Functional Imaging of Luminal Thrombus Activity in Abdominal Aortic Aneurysms
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2006;
26(9):
2153 - 2159.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Goerge, A. Barg, E.-M. Schnaeker, B. Poppelmann, V. Shpacovitch, A. Rattenholl, C. Maaser, T. A. Luger, M. Steinhoff, and S. W. Schneider
Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation.
Cancer Res.,
August 1, 2006;
66(15):
7766 - 7774.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. J. Marder, D. J. Chute, S. Starkman, A. M. Abolian, C. Kidwell, D. Liebeskind, B. Ovbiagele, F. Vinuela, G. Duckwiler, R. Jahan, et al.
Analysis of Thrombi Retrieved From Cerebral Arteries of Patients With Acute Ischemic Stroke
Stroke,
August 1, 2006;
37(8):
2086 - 2093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev,
April 1, 2006;
86(2):
515 - 581.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Touat, V. Ollivier, J. Dai, M.-G. Huisse, A. Bezeaud, U. Sebbag, T. Palombi, P. Rossignol, O. Meilhac, M.-C. Guillin, et al.
Renewal of Mural Thrombus Releases Plasma Markers and Is Involved in Aortic Abdominal Aneurysm Evolution
Am. J. Pathol.,
March 1, 2006;
168(3):
1022 - 1030.
[Abstract]
[Full Text]
[PDF]
|
 |
|